identification of the molecular basis of doxorubicin

Modulatory Effect of Aerobic Exercise Training on

We tested the hypothesis that aerobic exercise training (AET) would modulate doxorubicin-induced cardiotoxicity in rats of various ages Wistar male rats (n = 72) were assigned to three groups (young adult and elderly) with three subgroups for

The role of iron in anthracycline cardiotoxicity

The clinical use of the antitumor anthracycline Doxorubicin is limited by the risk of severe cardiotoxicity The mechanisms underlying anthracycline-dependent cardiotoxicity are multiple and remain uncompletely understood but many observations indicate that interactions with cellular iron metabolism are important Convincing evidence showing that iron plays a role in Doxorubicin

The Role of AMPK Activation for Cardioprotection in

Doxorubicin is a commonly used chemotherapeutic agent for the treatment of a range of cancers but despite its success in improving cancer survival rates doxorubicin is cardiotoxic and can lead to congestive heart failure Therapeutic options for this patient group are limited to standard heart failure medications with the only drug specific for doxorubicin cardiotoxicity to reach FDA

Identification of the molecular basis of doxorubicin

Identification of the molecular basis of doxorubicin-induced cardiotoxicity Sui Zhang Xiaobing Liu Tasneem Bawa-Khalfe Long Sheng Lu Yi Lisa Lyu Leroy F Liu Edward T H Yeh Cardiology Research output: Contribution to journal › Article 714 Scopus citations Abstract Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive

Molecular Mechanisms of the Cardiotoxicity of the

Bortezomib and carfilzomib are anticancer drugs that target the proteasome However these agents have been shown to exhibit some specific cardiac toxicities by as yet unknown mechanisms Bortezomib and carfilzomib are also being used clinically in combination with doxorubicin which is also cardiotoxic A primary neonatal rat myocyte model was used to study these cardiotoxic mechanisms

REFERENCES

Lyu YL Kerrigan JE Lin CP et al Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res 2007 67:8839 Zhang S Liu X Bawa-Khalfe T et al Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 2012 18:1639

The analysis of doxorubicin resistance in human breast

The identification of novel biomarkers which correlate with treatment response would allow therapy to be tailored on an individual patient basis Ultimately those patients unlikely to respond to doxorubicin would be spared from serious life-threatening side effects for no therapeutic gain Biomarkers may also provide information on new drug targets for future therapeutic intervention

Doxorubicin Impairs the Insulin

Zhang S Liu X Bawa-Khalfe T Lu LS Lyu YL Liu LF et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 18: 1639–1642 pmid:23104132 View Article PubMed/NCBI Google Scholar 31 Vejpongsa P Yeh ET (2014) Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities J Am

Identification of novel biomarkers for doxorubicin

Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells Gustav Holmgren a b Jane Synnergren a Yalda Bogestl a 1 Caroline Amen c Karolina kesson c Sandra Holmgren c Anders Lindahl b and Peter Sartipy a c 2

High Throughput Screening Identifies a Novel Compound

Antracyclines are effective antitumor agents One of the most commonly used antracyclines is doxorubicin which can be successfully used to treat a diverse spectrum of tumors Application of these drugs is limited by their cardiotoxic effect which is determined by a lifetime cumulative dose We set out to identify by high throughput screening cardioprotective compounds protecting

Identification of variable lymphocyte receptors that can

Diseases that lead to blood-brain barrier (BBB) disruption will pathologically expose normally inaccessible brain extracellular matrix (ECM) to circulating blood components Therefore we hypothesized that brain ECM-targeting moieties could specifically target the disrupted BBB and potentially deliver therapies Variable lymphocyte receptors (VLRs) that preferentially associate with brain ECM

Doxorubicin

Doxorubicin sold under the trade names Adriamycin among others is a chemotherapy medication used to treat cancer This includes breast cancer bladder cancer Kaposi's sarcoma lymphoma and acute lymphocytic leukemia It is often used together with other chemotherapy agents Doxorubicin is given by injection into a vein Common side effects include hair loss bone marrow suppression

Cardioprotection in cancer therapy: novel insights with

Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 2012 18: 1639 – 1642 Google Scholar Crossref Search ADS PubMed 7 Casper ES Gaynor JJ Hajdu SI Magill GB Tan C Friedrich C Brennan MF A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft

Determining the genetic basis of anthracycline

Many cancers including leukaemia lymphoma and breast cancer are treated with potent chemotherapy drugs such as anthracyclines However anthracyclines have strong side effects known as anthracycline cardiotoxicity which affect the health of the heart Almost half of the patients given high doses of anthracyclines develop chronic heart failure

Identification of the molecular basis of doxorubicin

Identification of the molecular basis of doxorubicin-induced cardiotoxicity Zhang S(1) Liu X Bawa-Khalfe T Lu LS Lyu YL Liu LF Yeh ET Author information: (1)Department of Cardiology The University of Texas MD Anderson Cancer Center Houston TX USA Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS

Identification of the molecular basis of doxorubicin

Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 2012 18(11):1639-42 (ISSN: 1546-170X) Zhang S Liu X Bawa-Khalfe T Lu LS Lyu YL Liu LF Yeh ET Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS) Here we show that cardiomyocyte-specific deletion of Top2b (encoding

Bioinformatics identification of potential candidate

The underlying molecular mechanism of doxorubicin-induced HF is not completely consistent with non-pharmaceutical HF Some potential more important indicators specified for doxorubicin-induced HF may be concealed by the validation with the study GSE9128 designed for the identification of non-pharmaceutical HF biomarkers For instance the present study showed that DEGs in GSE40447 were

Cardiotoxicity of cancer chemotherapy: identification

Cardiotoxicity of cancer chemotherapy: identification prevention and treatment Cardiotoxicity is an important complication of several cancer therapeutic agents Several well established and newer anticancer therapies such as anthracyclines trastuzumab and other HER2 receptor blockers antimetabolites alkylating agents tyrosine kinase inhibitors (TKIs) angiogenesis inhibitors and

Molecular basis for the action of a dietary flavonoid

The beneficial health effects of dietary phytochemicals make them promising candidates for treatment and prevention of multiple diseases However cellular targets for dietary components remain largely unknown By combining phage display with high-throughput sequencing we identified 160 human targets of apigenin a flavonoid abundant in fruits and vegetables

Identification of the molecular basis of doxorubicin

Identification of the molecular basis of doxorubicin-induced cardiotoxicity Sui Zhang Xiaobing Liu Tasneem Bawa-Khalfe Long Sheng Lu Yi Lisa Lyu Leroy F Liu Edward T H Yeh Cardiology Research output: Contribution to journal › Article 714 Scopus citations Abstract Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive

دانلود مقاله شناسایی مبنای مولکولی سمیت قلبی ناشی از

دانلود ترتیل قرآن با صدای استاد پرهیزکار به تفکیک سوره دانلود ترتیل قرآن با صدای استاد پرهیزکار به تفکیک جزء

Identification of Genes Required for Protection from

Identification of Genes Required for Protection from Doxorubicin by a Genome Screen for deletion strains that display increased sensitivity to doxorubicin To identify genes that protect cells from doxorubicin cytotoxicity we performed two screens on the set of ∼4 700 S cerevisiae haploid gene deletion library The concentration of doxorubicin that was used in the screen was determined

Maximizing the Benefit

The patient had a complete response to doxorubicin therapy with a cumulative dose of 1 350 mg/m2 which is significantly above the recommended limits and to our knowledge the highest dose reported in literature Two and a half years after the last doxorubicin cycle the patient is asymptomatic with no cardiotoxicity and an excellent quality of life This case highlights the importance of

Mitochondrial proteomics with siRNA knockdown to reveal

Mitochondrial proteomics with siRNA knockdown to reveal ACAT 1 and MDH 2 in the development of doxorubicin‐resistant uterine cancer Yi‐Wen Lo Department of Applied Science National Hsinchu University of Education Hsinchu Taiwan Equal contribution of these authors Search for more papers by this author Szu‐Ting Lin Institute of Bioinformatics and Structural Biology and Department

Cardiac Toxicity of Cancer Chemotherapy

Cardiac toxicity can occur with a broad range of cancer treatments from conventional cytotoxic agents to newer targeted and immune-based therapies Common manifestations of chemotherapy-associated cardiotoxicity include asymptomatic left ventricular dysfunction congestive heart failure myocardial ischemia myocarditis QT prolongation and arrhythmia In this review we will describe

How does doxorubicin work? (pdf)

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome Doxorubicin blocks proliferation of cancer cells through proteolytic Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1 Transcription factor CREB3L1 mediates cAMP and glucocorticoid regulation

Anthracycline – Wikipedia

Anthracycline oder Anthrazykline sind eine aus Streptomyces-Arten isolierte Stoffgruppe mit antibiotischen und antineoplastischen Wirkungen Chemisch handelt es sich um Glycoside mit einem Cyclohexan-anellierten Anthrachinon-Grundgerst dem 7 8 9 10-Tetrahydrotetracen-5 12-dion als Aglycon Neben weiteren Substituenten besitzen die Anthracycline mehrere Hydroxygruppen

Online customer service

Welcome ! If you have any questions or suggestions about our products and services,please feel free to tell us anytime!